Release number 20/2010 Interim report for the three months ended 31st March, 2010 Summary: For the first three months of 2010, Affitech A/S generated a loss of DKK 14.1 million. Revenues for the period were DKK 0.6 million. The net loss includes a net profit of DKK 5.9 million from sales of royalty and milestone rights deducted by DKK 4.0 million of goodwill that was connected to parts of these rights. The Company is now in the process of revising its operating plans for 2010 and 2011. The new financing will enable an increased R&D activity compared to the level previously reported. The company plans to give further information in June when the re-planning process is completed. For more information please contact: Affitech A/S: Randi Krogsgaard, Corporate Communications Tel # +45 2320 1001 About Affitech Affitech AS is a publicly traded (NASDAQ OMX Copenhagen exchange) human therapeutic antibody company headquartered in Copenhagen, Denmark with R&D facilities in Oslo, Norway. The company utilizes a range of proprietary antibody technologies for the discovery of fully human antibodies for application in oncology, inflammation and other disease areas. CBAS™ (Cell Based Antibody Selection) is Affitech's premier discovery engine for the isolation of lead antibodies to cell surface molecules in situ. Several of the Company's proprietary product candidates were generated by CBAS™. Further information is available at www.affitech.com. Disclaimer This news release contains forward-looking statements and forecasts based on uncertainty, since they relate to events and depend on circumstances that will occur in the future and which, by their nature, will have an impact on results of the financial condition and operations of Affitech A/S. There are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements and forecasts. These factors include, among other things, risks associated with technological development, the risk that research & development will not yield new products that achieve commercial success, the impact of competition, the ability to transact viable and profitable commercial deals, the risk of non-approval of patents not yet granted, and difficulties of obtaining relevant governmental approvals for new products. No expressed or implied representations or warranties are given concerning Affitech A/S or the accuracy or completeness of the information provided herein, and no claims shall be made by the recipient of this news release by virtue of the information contained herein. This is an English translation of the Group's first quarter announcement for 2010 made in Danish. In case of any discrepancies between the Danish version and this English translation thereof, the Danish version shall prevail.